New drug aims to tame severe eczema in kids and teens
NCT ID NCT06713499
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study tests an experimental drug called SHR-1819 in children and adolescents aged 6 to 17 with moderate-to-severe atopic dermatitis (a type of eczema). The main goal is to check the drug's safety and how the body processes it. Researchers will also look at changes in skin-related markers and whether the body develops antibodies against the drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-1819 injection
- What this could lead to
- If successful, this could provide a new treatment option for children and teens with moderate-to-severe atopic dermatitis.
- What could go wrong
- This is an early-phase trial with a small number of participants, so results may not apply to everyone. The drug may cause side effects or not work as expected.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHILDREN AND ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Children's Hospital, Capital Medical University
Beijing, Beijing Municipality, 100045, China
-
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, 110002, China